PT  - JOURNAL ARTICLE
AU  - Kuznar, Wayne
ED  - Tardif, Jean-Claude
TI  - First Clinical Evidence Offered That Inhibiting P-Selectin May Limit Myocardial Damage during PCI
DP  - 2013 May 01
TA  - MD Conference Express
PG  - 19--20
VI  - 13
IP  - 2
4099  - http://mdc.sagepub.com/content/13/2/19.2.short
4100  - http://mdc.sagepub.com/content/13/2/19.2.full
AB  - A single dose of inclacumab, a fully human recombinant monoclonal antibody directed against P-selectin, appears to reduce myocardial damage in patients undergoing percutaneous coronary intervention (PCI) as measured by biomarker concentration. Results from a randomized Phase 2 trial showed a reduction in levels of troponin I at 16 and 24 hours post PCI with a single dose of incalcumab 20 mg/kg when administered prior to PCI. The effect of a single dose of inclacumab on myocardial damage was examined in the Study of RO4905417 in Patients With Non ST-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention [SELECT-ACS; Tardif JC et al. J Am Coll Cardiol 2013].